How would gathering preclinical data and improving research infrastructure facilitate clearer definitions of “population vulnerability” and “risk acceptability”?
AMA J Ethics. 2020;22(1):E43-49. doi:
10.1001/amajethics.2020.43.
This process of developing EBM-based guidelines and applying them to clinical care highlights the tension between generating unbiased knowledge based on statistical aggregation and the application of this information to individual patients.
Elderly persons should not be excluded from participation in clinical trials for cardiovascular drugs since that population comprises the largest number of patients with cardiovascular disease.
Primary materials including interviews with some of the volunteer subjects provide information on the experiments into the pathogenic mechanism of yellow fever.